Navios Maritime Partners L.P. (NMM)

Intra-Cellular Therapies Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Intra-Cellular Therapies stock has a target of 80, which predicts a 91.85% increase from the current stock price of 41.7.

Price Target: $80.00 (+91.85%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$80	$80	$80	$80
Change	+91.85%	+91.85%	+91.85%	+91.85%

* Price targets were last updated on Sep 19, 2024.

Analyst Ratings

According to 1 stock analyst, the rating for Intra-Cellular Therapies is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Apr '24	May '24	Jun '24	Jul '24	Aug '24	Sep '24
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Randy Giveans Jefferies	Jefferies	Strong Buy Maintains $65 → $80	Strong Buy	Maintains	$65 → $80	+91.85%	Sep 19, 2024
Randy Giveans Jefferies	Jefferies	Strong Buy Maintains $15 → $20	Strong Buy	Maintains	$15 → $20	-52.04%	Jan 29, 2021
Randy Giveans Jefferies	Jefferies	Hold → Strong Buy Upgrades $7.5 → $15	Hold → Strong Buy	Upgrades	$7.5 → $15	-64.03%	Jan 8, 2021
Randy Giveans Jefferies	Jefferies	Hold Maintains $9 → $7	Hold	Maintains	$9 → $7	-83.21%	Oct 23, 2020
Prashant Rao Citigroup	Citigroup	Hold Maintains $34 → $22	Hold	Maintains	$34 → $22	-48.44%	Sep 20, 2019

More Analyst Ratings

Financial Forecast

Revenue This Year

1.24B

Decreased by -7.35%

from 1.33B

Revenue Next Year

1.33B

Increased by 7.93%

from 1.24B

EPS This Year

10.98

Decreased by -9.38%

from 12.12

EPS Next Year

13.37

Increased by 21.80%

from 10.98

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	226.77M	713.18M	1.21B	1.31B	1.33B	1.24B	1.33B	1.49B
Revenue Growth	3.37%	214.49%	69.74%	7.96%	2.08%	-7.35%	7.93%	11.39%
EPS	-5.92	16.75	18.80	14.08	12.12	10.98	13.37	13.84
EPS Growth	-	-	12.26%	-25.14%	-13.93%	-9.38%	21.80%	3.47%
Forward PE	-	-	-	-	-	3.80	3.12	3.01
No. Analysts	-	-	-	-	-	3	3	2

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	1.4B	1.5B	1.5B
Avg	1.2B	1.3B	1.5B
Low	1.1B	1.2B	1.4B

Revenue Growth

Revenue Growth	2025	2026	2027
High	3.4%	22.2%	15.8%
Avg	-7.4%	7.9%	11.4%
Low	-16.6%	-4.5%	8.1%

EPS Forecast

EPS	2025	2026	2027
High	11.41	13.90	14.39
Avg	10.98	13.37	13.84
Low	10.65	12.98	13.43

EPS Growth

EPS Growth	2025	2026	2027
High	-5.8%	26.6%	7.6%
Avg	-9.4%	21.8%	3.5%
Low	-12.1%	18.2%	0.4%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.